title: Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Eliezer M
authors.initials: EM
authors.lastname: Van Allen
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Levi A
authors.initials: LA
authors.lastname: Garraway
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: rosenbj1@mskcc.org.
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Rosenberg
mesh_terms: D006801:Humans; D009154:Mutation; D020360:Neoadjuvant Therapy; D011471:Prostatic Neoplasms; D001749:Urinary Bladder Neoplasms